Cite
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
MLA
Schadendorf, Dirk, et al. “Health-Related Quality of Life with Nivolumab plus Relatlimab versus Nivolumab Monotherapy in Patients with Previously Untreated Unresectable or Metastatic Melanoma: RELATIVITY-047 Trial.” European Journal of Cancer, vol. 187, July 2023, pp. 164–73. EBSCOhost, https://doi.org/10.1016/j.ejca.2023.03.014.
APA
Schadendorf, D., Tawbi, H., Lipson, E. J., Stephen Hodi, F., Rutkowski, P., Gogas, H., Lao, C. D., Grob, J.-J., Moshyk, A., Lord-Bessen, J., Hamilton, M., Guo, S., Shi, L., Keidel, S., & Long, G. V. (2023). Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. European Journal of Cancer, 187, 164–173. https://doi.org/10.1016/j.ejca.2023.03.014
Chicago
Schadendorf, Dirk, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, et al. 2023. “Health-Related Quality of Life with Nivolumab plus Relatlimab versus Nivolumab Monotherapy in Patients with Previously Untreated Unresectable or Metastatic Melanoma: RELATIVITY-047 Trial.” European Journal of Cancer 187 (July): 164–73. doi:10.1016/j.ejca.2023.03.014.